Larrick J W, Gray O, Deinhart T, Wang J, Flatgaard J, Chong K T
Department of Immunology, Cetus Corporation, Palo Alto, California 94303.
Prog Clin Biol Res. 1988;272:383-93.
Using a combination of Epstein-Barr virus transformation and cell fusion to a mouse/human heteromyeloma cell line, we have generated a human monoclonal antibody, D234, that recognizes cross-reactive determinants on the lipopoly-saccharides (LPS) of Gram-negative bacteria. Direct binding to a series of rough mutant LPSs and smooth LPSs demonstrates the broad cross-reactivity of this monoclonal. D234 inhibits Re LPS-induced chemiluminescence. In a murine model of Gram-negative sepsis, D234 given after infection significantly increases survival. This antibody may have therapeutic potential for the treatment of life-threatening Gram-negative infections in humans.
通过将爱泼斯坦-巴尔病毒转化与细胞融合至小鼠/人异源骨髓瘤细胞系相结合的方法，我们制备了一种人单克隆抗体D234，它能识别革兰氏阴性菌脂多糖（LPS）上的交叉反应性决定簇。与一系列粗糙突变型LPS和平滑型LPS的直接结合证明了该单克隆抗体具有广泛的交叉反应性。D234可抑制Re LPS诱导的化学发光。在革兰氏阴性菌败血症的小鼠模型中，感染后给予D234可显著提高生存率。这种抗体可能对治疗人类危及生命的革兰氏阴性菌感染具有治疗潜力。
